Parkinson's Disease Protocol

Neurological HealthModerate Evidence

supplements

Primary

Supporting

Grade A

Studies

Primary Stack

Core supplements with strongest evidence

Mucuna PruriensA

15-30g seed powder (standardized for L-DOPA content) under medical supervision

Natural source of L-DOPA, the precursor to dopamine; may provide symptomatic benefit similar to pharmaceutical levodopa

↓Parkinson's Disease Symptoms

12 studies400 participants

Supporting Studies (2)

PMID: 28867867 - Mucuna pruriens in Parkinson's disease: systematic review (2017)PMID: 15548480 - Mucuna pruriens vs synthetic levodopa: clinical trial (2004)

Coenzyme Q10B

300-1200mg daily (higher doses studied for neuroprotection)

Supports mitochondrial function and may slow disease progression; addresses mitochondrial dysfunction in Parkinson's

↓Parkinson's Disease Symptoms

15 studies1,000 participants

Supporting Studies (2)

PMID: 12374491 - CoQ10 for early Parkinson's disease: RCT (2002)PMID: 28784268 - CoQ10 for Parkinson's: updated meta-analysis (2017)

Supporting Stack

Additional supplements for enhanced results

Vitamin DB

2000-4000 IU daily (based on blood levels)

Deficiency highly prevalent in PD; supplementation may support motor function and reduce falls

↑6-Minute Walking Test Performance↓Parkinson's Disease Symptoms↑Walking Ability

15 studies800 participants

Supporting Studies (1)

PMID: 28934481 - Vitamin D and Parkinson's disease: systematic review (2017)

CreatineC

5-10g daily

Supports brain energy metabolism and may have neuroprotective effects; helps maintain muscle mass

Parkinson's Disease Symptoms↑Power Output↑Subjective Well-Being

8 studies500 participants

Supporting Studies (1)

PMID: 17312085 - Creatine for Parkinson's disease: clinical trial (2006)

Omega-3 Fatty AcidsC

2-4g EPA/DHA daily

Anti-inflammatory and neuroprotective; supports brain cell membrane health

8 studies400 participants

Supporting Studies (1)

PMID: 29891075 - Omega-3 in neurodegenerative diseases: review (2018)

CurcuminC

500-1000mg daily (enhanced absorption formula)

Crosses blood-brain barrier; anti-inflammatory and may inhibit alpha-synuclein aggregation

6 studies200 participants

Supporting Studies (1)

PMID: 30040036 - Curcumin neuroprotection in Parkinson's: review (2018)

N-Acetylcysteine (NAC)C

600-1800mg daily

Replenishes glutathione, which is depleted in Parkinson's; antioxidant support for dopaminergic neurons

6 studies200 participants

Supporting Studies (1)

PMID: 30211050 - NAC for Parkinson's disease: pilot study (2018)

How This Protocol Works

Simple Explanation

Parkinson's disease is a progressive neurological condition caused by the death of dopamine-producing neurons in a brain area called the substantia nigra. This leads to motor symptoms (tremor, rigidity, slowness of movement, balance problems) and non-motor symptoms (depression, sleep problems, cognitive changes, constipation). The disease involves mitochondrial dysfunction, oxidative stress, and accumulation of a protein called alpha-synuclein. While medications like levodopa/carbidopa are the mainstay of treatment, certain supplements may provide additional support.

IMPORTANT: These supplements are meant to complement, not replace, your neurologist's treatment plan. Mucuna pruriens in particular contains L-DOPA and can interact with Parkinson's medications—use only under medical supervision.

•Mucuna Pruriens (velvet bean) is a natural source of L-DOPA, the same compound that's converted to dopamine in the brain and is the basis for levodopa medication. Studies show Mucuna may provide comparable symptom relief to synthetic levodopa, with potentially fewer side effects like dyskinesia. However, the L-DOPA content varies between products, making dosing challenging. It must be used under neurologist supervision, especially if already taking levodopa medications.

•Coenzyme Q10 supports the mitochondria, which are impaired in Parkinson's. Early studies showed that high doses (1200mg/day) might slow disease progression, though a large later trial was stopped for futility. CoQ10 is still considered reasonable for its antioxidant properties and cardiac benefits (important since many PD meds affect the heart).

•Vitamin D deficiency is extremely common in Parkinson's patients and is associated with worse motor symptoms and increased falls. Supplementation may improve motor function and reduce fracture risk from falls—a major concern in PD.

•Creatine supports brain energy metabolism and has shown neuroprotective effects in laboratory studies. While large clinical trials haven't shown major benefit for slowing progression, it helps maintain muscle mass and strength, which is important for mobility.

•Omega-3 Fatty Acids have anti-inflammatory and neuroprotective properties. They support brain cell membrane health and may help with depression, which is common in Parkinson's.

•Curcumin can cross the blood-brain barrier and has been shown in laboratory studies to inhibit the aggregation of alpha-synuclein (the protein that clumps in Parkinson's). It also has powerful anti-inflammatory effects. Clinical evidence is still preliminary.

•N-Acetylcysteine (NAC) replenishes glutathione, the brain's major antioxidant, which is significantly depleted in Parkinson's patients. Early studies show it may reach the brain and increase dopamine transporter availability.

Expected timeline: Mucuna: effects similar to levodopa timing (within days-weeks). CoQ10/creatine: ongoing neuroprotective support. Vitamin D: 2-3 months. Curcumin/NAC: 4-8 weeks for potential benefits.

Clinical Perspective

Parkinson's disease involves progressive degeneration of dopaminergic neurons in the substantia nigra pars compacta. Pathological hallmarks include Lewy bodies (alpha-synuclein aggregates), mitochondrial complex I dysfunction, oxidative stress, neuroinflammation, and glutathione depletion. Motor symptoms emerge when ~60-80% of striatal dopamine is lost. Non-motor features (RBD, constipation, hyposmia, depression) often precede motor symptoms. Standard treatment is dopaminergic (levodopa, dopamine agonists, MAO-B inhibitors).

CRITICAL: Supplements containing L-DOPA (Mucuna) must be coordinated with neurologist due to interactions with carbidopa/levodopa and risk of fluctuations. Many supplements affect CYP enzymes—check interactions with Parkinson's medications.

•Mucuna Pruriens (A-grade): Seeds contain 4-6% L-DOPA naturally. Historically used in Ayurveda for 'kampavata' (tremor disease). Clinical trial: 30g Mucuna powder comparable to carbidopa/levodopa for motor response, with potentially faster onset and longer duration without worsening dyskinesias (PMID: 15548480). Systematic review confirms efficacy (PMID: 28867867). Variable L-DOPA content between products problematic. Contains other potentially beneficial compounds. Requires medical supervision; cannot be combined freely with levodopa.

•Coenzyme Q10 (B-grade): Electron carrier in mitochondrial complex I (deficient in PD). Antioxidant in lipid membranes. Early RCT: 1200mg/day showed trend toward slowing functional decline (PMID: 12374491). Large Phase III trial (QE3) stopped for futility—no slowing of progression at 1200-2400mg. Meta-analysis: modest improvement in UPDRS-III motor scores (PMID: 28784268). May still benefit cardiac function and quality of life. 300-1200mg/day.

•Vitamin D (B-grade): Deficiency in 55-89% of PD patients. Vitamin D receptors in substantia nigra; influences dopamine synthesis genes and has neurotrophic effects. Systematic review: deficiency correlates with motor severity; supplementation may improve motor function (PMID: 28934481). Critical for bone health and fall prevention. Target 25(OH)D >30-40 ng/mL; 2000-4000 IU/day.

•Creatine (C-grade): Enhances brain phosphocreatine (energy buffer). Neuroprotective in MPTP models. Clinical trial: well-tolerated, maintains muscle function (PMID: 17312085). Large NET-PD LS-1 trial showed no significant slowing of progression. Still reasonable for muscle maintenance (sarcopenia common in PD). 5-10g/day.

•Omega-3 Fatty Acids (C-grade): DHA incorporated into neuronal membranes; anti-inflammatory (inhibits microglial activation). Review supports role in neurodegeneration (PMID: 29891075). May benefit depression in PD. Limited PD-specific clinical data. 2-4g EPA/DHA daily.

•Curcumin (C-grade): Crosses BBB; inhibits alpha-synuclein aggregation, reduces neuroinflammation (NF-κB inhibition), chelates iron, and has antioxidant properties. Review of preclinical evidence supports neuroprotective potential (PMID: 30040036). Limited clinical data in PD. Bioavailability critical—use enhanced formulations. 500-1000mg/day.

•N-Acetylcysteine (NAC) (C-grade): Glutathione precursor. Substantia nigra glutathione depleted by 40-50% in PD. Pilot study: oral + IV NAC increased brain glutathione (MRS) and improved dopamine transporter binding (DaTscan) (PMID: 30211050). Promising mechanism but early-stage evidence. 600-1800mg/day oral; IV protocols in research settings.

Biomarker targets: UPDRS scores (motor and non-motor), Hoehn & Yahr staging, MoCA (cognition), PDQ-39 (quality of life), non-motor symptom scale, 25(OH)D, fall frequency, DaTscan if diagnostic uncertainty, depression screening (PHQ-9).

Protocol notes: Physical therapy and exercise (especially aerobic, high-intensity, and boxing/dance) have strong evidence for improving motor function and possibly neuroprotection. Speech therapy (LSVT LOUD) for hypophonia. Occupational therapy for ADLs. Optimize levodopa timing (protein interactions affect absorption). Address orthostatic hypotension. Constipation management (fiber, hydration, PEG). Sleep hygiene for RBD/insomnia. Depression screening and treatment. Cognitive rehabilitation if MCI. Fall prevention strategies. Advanced therapies (DBS, pump infusions) for motor fluctuations. Palliative care discussion for advanced disease. Caregiver support essential.

View All Protocols